What is Lifesci Capital’s Forecast for PBLS Q2 Earnings?

Parabilis Medicines, Inc. (NASDAQ:PBLS) – Stock analysts at Lifesci Capital issued their Q2 2026 earnings per share (EPS) estimates for Parabilis Medicines in a research report issued to clients and investors on Monday, July 6th. Lifesci Capital analyst C. Zhu expects that the company will post earnings per share of $0.09 for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. Lifesci Capital also issued estimates for Parabilis Medicines’ Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.00) EPS, Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.30) EPS, Q4 2027 earnings at ($0.30) EPS and FY2027 earnings at ($1.19) EPS.

Other research analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of Parabilis Medicines to a “hold” rating in a research report on Saturday, June 20th. Evercore initiated coverage on Parabilis Medicines in a research note on Monday. They issued an “outperform” rating for the company. Leerink Partners initiated coverage on Parabilis Medicines in a research report on Monday. They set an “outperform” rating and a $40.00 price target on the stock. Guggenheim initiated coverage on Parabilis Medicines in a report on Monday. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Bank of America assumed coverage on Parabilis Medicines in a research note on Monday. They set a “buy” rating and a $45.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $41.67.

Parabilis Medicines Stock Performance

Parabilis Medicines stock opened at $30.35 on Wednesday. Parabilis Medicines has a 52 week low of $24.51 and a 52 week high of $34.47.

Insiders Place Their Bets

In related news, major shareholder Guy Levy acquired 500,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was purchased at an average cost of $20.00 per share, with a total value of $10,000,000.00. Following the acquisition, the insider directly owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. The trade was a 94.88% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan Sebulsky bought 12,500 shares of Parabilis Medicines stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the acquisition, the director owned 12,500 shares in the company, valued at $250,000. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 530,000 shares of company stock worth $10,723,528.

Key Headlines Impacting Parabilis Medicines

Here are the key news stories impacting Parabilis Medicines this week:

• Positive Sentiment: Lifesci Capital upgraded Parabilis Medicines (PBLS) to Strong-Buy, signaling improved confidence in the company’s outlook. Tickerreport.com
• Positive Sentiment: Guggenheim initiated coverage with a Buy rating and a $40 price target, implying meaningful upside from current levels. Tickerreport.com
• Positive Sentiment: Bank of America started coverage with a Buy rating and a $45 price target, another bullish signal for investors. American Banking News
• Positive Sentiment: Leerink Partners also initiated coverage with an Outperform rating and a $40 price target, adding to the positive analyst momentum. American Banking News
• Positive Sentiment: Evercore began coverage with an Outperform rating, further supporting the market’s constructive view of PBLS. The Fly